As the NK community remains determined as ever to prove the advantages of NK cells, the year of the ‘bounce back’ now feels within reach. Driven by expansion into autoimmune pipelines, Artiva’s $160M IPO marks a sizeable return of investment into this space. It is now business critical for NK developers to capitalize on the new momentum building and showcase clinically validated pipelines to investors to demonstrate the potential of NK therapies and bring long lasting benefit to patients in need. 

Returning to San Diego for its 10th Anniversary, the 10th Annual Innate Killer Summit continues to unite long-standing senior pioneers and trailblazers in the NK space. As the only dedicated platform to advancing development of NK engager, NK bispecific, cell therapy and cytokine-based approaches to the clinic with improved persistence and efficacy, you won’t want to miss out. 

Join 30+ wave-makers including Indapta Therapeutics, Genentech, Katy Rezvani’s Lab and Artiva Bio as they pave the way to revolutionizing allogeneic and innate immunity treatment.